We are live on ! Find out more
RXII

GALENA BIOPHARMA INC COM
RXII

Delisted

RXII was delisted on the 25th of October, 2011.

Back to rankings

0 hedge funds and large institutions have $0 invested in GALENA BIOPHARMA INC COM in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 90 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 91 → 0 (-91)

100% less capital invested

Capital invested by funds: $11.5M → $0 (-$11.5M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 90

Holders
–
Holders Change
-91
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
90
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$2.93M
2
BFA
BlackRock Fund Advisors
California
-$2.11M
3
BIT
BlackRock Institutional Trust
California
-$1.54M
4
State Street
State Street
Massachusetts
-$1.01M
5
Northern Trust
Northern Trust
Illinois
-$715K
Name Holding Trade Value Shares
Change 		Change in
Stake
BA
26
BlackRock Advisors
Delaware
– -$37K -106,061 Closed
AIG
27
American International Group
New York
– -$37K -105,733 Closed
CS
28
Credit Suisse
Switzerland
– -$30K -88,987 Closed
VOYA Investment Management
29
VOYA Investment Management
Georgia
– -$29 -82,079 Closed
TSS
30
Two Sigma Securities
New York
– -$27K -77,568 Closed
State Board of Administration of Florida Retirement System
31
State Board of Administration of Florida Retirement System
Florida
– -$24K -67,930 Closed
T. Rowe Price Associates
32
T. Rowe Price Associates
Maryland
– -$21K -59,906 Closed
Mariner
33
Mariner
Kansas
– -$19K -53,000 Closed
PRCM
34
Pine River Capital Management
Minnesota
– -$18K -50,665 Closed
PHK
35
Point72 Hong Kong
Hong Kong
– -$18K -50,300 Closed
UCFA
36
United Capital Financial Advisors
Texas
– -$18K -50,000 Closed
Citadel Advisors
37
Citadel Advisors
Florida
– -$17K -47,821 Closed
Commonwealth Equity Services
38
Commonwealth Equity Services
Massachusetts
– -$15K -42,715 Closed
Manulife (Manufacturers Life Insurance)
39
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$15K -41,965 Closed
DBIA
40
Dumont & Blake Investment Advisors
New Jersey
– -$14K -39,000 Closed
Deutsche Bank
41
Deutsche Bank
Germany
– -$12K -35,472 Closed
Ameriprise
42
Ameriprise
Minnesota
– -$12K -35,149 Closed
SG Americas Securities
43
SG Americas Securities
New York
– -$12K -34,197 Closed
Principal Financial Group
44
Principal Financial Group
Iowa
– -$11K -31,755 Closed
LTFS
45
Ladenburg Thalmann Financial Services
Florida
– -$11K -30,125 Closed
Citigroup
46
Citigroup
New York
– -$11K -30,071 Closed
OC
47
Oppenheimer & Co
New York
– -$11K -29,600 Closed
MCP
48
Mirador Capital Partners
California
– -$10K -29,195 Closed
AW
49
ACG Wealth
Georgia
– -$9K -25,000 Closed
CCM
50
Compton Capital Management
Rhode Island
– -$10K -25,000 Closed
1
2
3 4

RXII Hedge Fund Activity: Q4 2016 in Review

0 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in GALENA BIOPHARMA INC COM (RXII) for Q4 2016, worth a combined $0 — down 100% from $11.5M a quarter earlier.

Sellers outnumbered buyers: 90 funds closed out of RXII and 0 opened new positions — a net loss of 90 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $2.93M sold.

  • 0 institutional investors held GALENA BIOPHARMA INC COM (RXII) as of Q4 2016, down from 91 in Q3 2016.
  • Funds reported $0 of GALENA BIOPHARMA INC COM stock for Q4 2016, down 100% quarter-over-quarter.
  • 0 funds opened new GALENA BIOPHARMA INC COM positions in Q4 2016 and 90 closed out, a net change of -90 holders.
  • The largest GALENA BIOPHARMA INC COM seller in Q4 2016 was Vanguard Group, an estimated $2.93M sold.

Based on aggregated 13F filings for Q4 2016.